UK Regulatory Science community meets to discuss the future of UK Medicine Regulation

UK Bioindustry Association (BIA) host industry and MHRA leaders at “The Future of UK Regulation Conference 2023” 

London, UK, 3 October, 2023 -  Leaders in medicines regulatory science are meeting to chart the course for the future of UK medicine regulation on 5 October at 11 Cavendish Square, London.  

The high-profile event is bringing together over 200 industry thought leaders, international stakeholders and regulatory experts with the senior leadership of the UK’s healthcare regulatory agency, the MHRA.  

Conference participants will be able to hear directly from expert speakers, including Dr June Raine DBE, CEO of the MHRA, Lord James O'Shaughnessy, who conducted a review into clinical trial effectiveness for the government earlier this year, and Professor Lucy Chappell, head of the National Institute for Health Research (NIHR).  

The conference will provide the latest developments, tackling insightful topics, at a time of significant change, challenge and opportunity: 

  • Getting UK clinical trials back on track 
  • The new international recognition framework for medicines – enabling access to innovation as a UK USP  
  • Latest thinking in approaches to the regulation of novel technologies – with a focus on how the application of artificial intelligence to the drug discovery and development process is best handled.   

Commenting on the conference, Steve Bates, CEO of the BIA said: “By bringing together the great minds we have in UK regulatory science, from both our regulatory agency and our leading life science companies, I believe the UK has an opportunity to rapidly develop practical regulatory procedures in new areas that can play a key role on the world stage.  

“The greatest strength of the UK life science ecosystem is innovation, and we know that it’s the intersection of new technologies, the machine learning from artificial intelligence allied to the greater understanding of cell biology from institutions like the Francis Crick Institute that is driving the next generation of companies, products and services.  

“With a laser-like focus on our strengths and a regulatory science mindset, I have every expectation that a practical collaborative innovation agenda will emerge from the day’s expert discussions.” 

Dr June Raine DBE, CEO of MHRA said: “At a time of ever-evolving challenges for global health, experts and industry leaders from the UK continue to provide pioneering solutions, keeping this country at the centre of global healthcare innovation. 

“To enable these world-leading industry efforts, regulators in the UK are also innovating hard, through new pathways and support systems to ensure patient access to the safe and effective products they need at the earliest opportunity. 

“By bringing together regulators and industry leaders through the BIA to address the biggest global healthcare challenges, we can continue to establish the UK as a world-leading home for the global life sciences industry and a place where medical innovation can flourish.” 

- Ends. -


Media Contacts

For more information or to attend, contact Alina O’Keeffe, Head of Marketing and Membership Communications, BIA on [email protected]  

Limited tickets for regulatory professionals are available.


More news and updates 

BIA responds to the Chancellor's Autumn Statement 2023

Life science spin-outs, start-ups and scale-ups are key drivers of the UK’s innovation-based economy and crucial for discovering and developing new medicines to save lives in the NHS. The UK is home to a third of life science startups founded in Europe since 2012 and companies like them are responsible for nearly two-thirds of medicines being developed globally.

bioProcessUK to celebrate biotech’s shining stars 

The BioIndustry Association (BIA) will honour two distinguished individuals for their exceptional contributions to the innovative life sciences and biotech sector.

UK biotech fundraising picks up with best quarterly total since 2021

The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

Rare disease companies call for UK leadership in supporting access to new treatments

A group of companies developing innovative new medicines for rare diseases, working together through their trade association, is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice both in the UK and internationally, to improve access to new treatments for patients.

UK TechBio driving AI revolution in drug discovery and patient care

AI, gene editing, engineering biology, and investor interest drive growth in UK bioeconomy.

UK set to lead global delivery of next-generation mRNA medicines

BIA's new explainer shows how the UK is leading the way in mRNA, a strategic technology of the future.


More within